“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Andrew Booth Biography and Net Worth

CFO of AbCellera Biologics

Andrew became AbCellera’s CFO in 2019 after spending nearly 4 years on the company’s Board of Directors. Prior to joining AbCellera, Andrew spent 10 years at STEMCELL Technologies where he held roles as the CFO and the Chief Commercial Officer. Before STEMCELL, Andrew spent 7 years at General Electric, ending by leading M&A/Business Development for GE Healthcare’s Europe, Middle East, and Africa business and GE Healthcare’s global Life Sciences business based in London. Andrew is Chairman for Precision Nanosystems and a Director at the National Board of Canadian Manufacturers and Exporters. He is also a former Director at the BC Tech Association, at Life Sciences BC and at Light Integra Inc. Andrew holds an MBA from INSEAD and a BASc in Engineering Physics from the University of British Columbia.

What is Andrew Booth's net worth?: The estimated net worth of Andrew Booth is at least $422,280.00 as of May 26th, 2023. Mr. Booth owns 153,000 shares of AbCellera Biologics stock worth more than $422,280 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Booth may own. Additionally, Mr. Booth receives a salary of $674,550.00 as CFO at AbCellera Biologics. Learn More about Andrew Booth's net worth.
How old is Andrew Booth?: Mr. Booth is currently 50 years old. There are 5 older executives and no younger executives at AbCellera Biologics. The oldest executive at AbCellera Biologics is Mr. Tryn T. Stimart Esq., J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer, who is 54 years old. Learn More on Andrew Booth's age.
What is Andrew Booth's salary?: As the CFO of AbCellera Biologics Inc., Mr. Booth earns $674,550.00 per year. There are 2 executives that earn more than Mr. Booth. The highest earning executive at AbCellera Biologics is Dr. Carl L.G. Hansen Ph.D., CEO, President & Chairperson, who commands a salary of $714,940.00 per year. Learn More on Andrew Booth's salary.
How do I contact Andrew Booth?: The corporate mailing address for Mr. Booth and other AbCellera Biologics executives is , , . AbCellera Biologics can also be reached via phone at 604-559-9005 and via email at [email protected]. Learn More on Andrew Booth's contact information.
Has Andrew Booth been buying or selling shares of AbCellera Biologics?: Andrew Booth has not been actively trading shares of AbCellera Biologics within the last three months. Most recently, on Friday, May 26th, Andrew Booth bought 14,500 shares of AbCellera Biologics stock. The stock was acquired at an average cost of $6.85 per share, with a total value of $99,325.00. Following the completion of the transaction, the chief financial officer now directly owns 153,000 shares of the company's stock, valued at $1,048,050. Learn More on Andrew Booth's trading history.
Who are AbCellera Biologics' active insiders?: AbCellera Biologics' insider roster includes Andrew Booth (CFO), John Hamer (Director), Carl Hansen (CEO), Michael Hayden (Director), Veronique Lecault (COO), Andrew Lo (Director), and John Montalbano (Director). Learn More on AbCellera Biologics' active insiders.

Andrew Booth Insider Trading History at AbCellera Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/26/2023	Buy	14,500	$6.85	$99,325.00	153,000
5/12/2022	Buy	85,000	$5.79	$492,150.00	138,500
11/11/2021	Buy	53,500	$14.74	$788,590.00
6/9/2021	Sell	1,200,000	$25.50	$30,600,000.00

Andrew Booth Buying and Selling Activity at AbCellera Biologics

AbCellera Biologics Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Today's Range

Now: $2.76

$2.71

$2.83

50 Day Range

MA: $2.69

$2.44

$3.15

2 Week Range

Now: $2.76

$2.34

$6.05

Volume

1,802,860 shs

Average Volume

1,696,099 shs

Market Capitalization

$815.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

From Weiss Ratings | Ad